Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2016; 05(03): 093-095
DOI: 10.4103/2278-330X.187563
Editorial Commentary

Lung cancer in India: Current status and promising strategies

P. M. Parikh
Asian Cancer Institute, KJ Somaiya Ayurvihar, Mumbai, Maharashtra
,
A. A. Ranade
Avinash Cancer Clinic, Pune, Maharashtra
,
Babu Govind
Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka
,
N. Ghadyalpatil
Yashoda Hospital, Hyderabad, Telangana
,
R. Singh
HCG Cancer Center, New Delhi
,
R. Bharath
Kovai Hospital, Coimbatore, Tamil Nadu
,
G. S. Bhattacharyya
Fortis Hospital, Kolkata, West Bengal
,
S. Koyande
Indian Cancer Society, Mumbai, Maharashtra
,
M. Singhal
Indraprastha Apollo Hospital, New Delhi
,
A. Vora
Max Hospital, New Delhi
,
A. Verma
Max Hospital, New Delhi
,
S. Hingmire
Deenanath Mangeshkar Hospital, Pune, Maharashtra
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 December 2020

© 2016. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parikh PM, editor. Lung Cancer Monograph 2012. ICP, API; 2012.
  • 2 Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
  • 3 Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29:4129-36.
  • 4 Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
  • 5 Hirsch FR, Varella-Garcia M, Bunn PA Jr., Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42.
  • 6 Parikh P, Puri T. Personalized medicine: Lung cancer leads the way. Indian J Cancer 2013;50:77-9.
  • 7 Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55.
  • 8 Parikh PM. Treatment of lung cancer in the elderly. Inj J Med Peadiatr Oncol 1999;2:140-7.
  • 9 Vanita N, Pinnati R, Joshi A, Patil VM, Prabhash K. Lung cancer in the Indian subcontinent. SAJC 2016;5:95-103.
  • 10 Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Last accessed on 2016 Feb 20].
  • 11 Available from: http://www.indiancancersociety.org/cancer-registry/cancer-registry.aspx. [Last accessed on 2016 Feb 20].
  • 12 Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 2013;8:e76164.
  • 13 Noronha V, Joshi A, Gokarn A, Sharma V, Patil V, Janu A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract 2014;2014:856156.
  • 14 Veldore VH, Patil S, Prabhudesai S, Satheesh CT, Shashidhara HP, Krishnamoorthy N, et al. Targeted therapy management in NSCLC patients using cytology: Experience from a tertiary care cancer center. Mol Diagn Ther 2016;20:119-23.
  • 15 Available from: http://www.cancerprogress.net/cca/advance-year-cancer-immunotherapy. [Last accessed on 2016 Feb 20].
  • 16 Juntu J, Sijbers J, De Backer S, Rajan J, Van Dyck D. Machine learning study of several classifiers trained with texture analysis features to differentiate benign from malignant soft-tissue tumors in T1-MRI images. J Magn Reson Imaging 2010;31:680-9.
  • 17 Walia S, Sharma S, Markand Kulurkar P, Patial V, Acharya A. A bimodal molecular imaging probe based on chitosan encapsulated magneto-fluorescent nanocomposite offers biocompatibility, visualization of specific cancer cells in vitro and lung tissues in vivo. Int J Pharm 2016;498:110-8.
  • 18 Sampedro F, Escalera S, Domenech A, Carrio I. A computational framework for cancer response assessment based on oncological PET-CT scans. Comput Biol Med 2014;55:92-9.